The BEATcc study (ENGOTCx10/GEICO 68-C/JGOG1084/GOG-3030, NCT03556839) is a multicenter, randomized Phase III trial evaluating the efficacy of atezolizumab (anti-PD-L1 antibody) in combination with platinum-based chemotherapy plus bevacizumab in patients with metastatic, recurrent, or persistent cervical cancer (regardless of PD-L1 expression levels) [85]. Here, CD274 is linked to cervical cancer.